WXIBF (WuXi Biologics (Cayman)) EBIT per Share : $0.12 (TTM As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) EBIT per Share?

WuXi Biologics (Cayman)'s EBIT per Share for the six months ended in Jun. 2024 was $0.07. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.12.

During the past 12 months, the average EBIT per Share Growth Rate of WuXi Biologics (Cayman) was -14.10% per year. During the past 3 years, the average EBIT per Share Growth Rate was 31.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 47.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for WuXi Biologics (Cayman)'s EBIT per Share or its related term are showing as below:

WXIBF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 31.2 Med: 60.9 Max: 112
Current: 31.2

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of WuXi Biologics (Cayman) was 112.00% per year. The lowest was 31.20% per year. And the median was 60.90% per year.

WXIBF's 3-Year EBIT Growth Rate is ranked better than
82.34% of 1257 companies
in the Biotechnology industry
Industry Median: 3.2 vs WXIBF: 31.20

WuXi Biologics (Cayman)'s EBIT for the six months ended in Jun. 2024 was $286 Mil.

WuXi Biologics (Cayman) EBIT per Share Historical Data

The historical data trend for WuXi Biologics (Cayman)'s EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) EBIT per Share Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.04

0.07

0.14

0.18

0.14

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial														0.10	0.08	0.08	0.06	0.07

WuXi Biologics (Cayman) EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

WuXi Biologics (Cayman)'s EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	606.746	/	4348.874
=	0.14

WuXi Biologics (Cayman)'s EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	286.221	/	4255.857
=	0.07

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.12

WuXi Biologics (Cayman) (OTCPK:WXIBF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

WuXi Biologics (Cayman) EBIT per Share Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

WXXWY:USA 02269:Hong Kong 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.